The acquisition creates a premier oncology portfolio for the validation of novel cancer therapies
Charles River Laboratories has acquired Oncotest, a German contract research organisation (CRO) providing discovery services for oncology for €34m.
In addition to the initial purchase price, the deal includes a potential additional payment of €2m based on future performance.
Freiburg-based Oncotest offers an integrated portfolio of target discovery and validation services for preclinical oncology researchers. The company specialises in in vivo pharmacology services, leveraging an extensive collection of more than 400 patient-derived xenograft (PDX) tumour models, as well as a full range of in vitro assays using commercially available and proprietary PDX-derived cell lines.
James Foster, Chairman, President and Chief Executive of Charles River, said: 'Global biopharmaceutical clients are increasingly demanding a full suite of oncology capabilities from a single partner, including PDX tumour models, cell lines, imaging services, and immuno-oncology tools. With Oncotest, Charles River Discovery Services now has one of the most comprehensive and translational portfolios of oncology discovery services in the early-stage CRO industry.'
Oncotest has become part of Charles River’s In Vivo Discovery business, which is part of the Discovery and Safety Assessment segment.